Liquid sedatives names. List of sedative drugs for osteochondrosis: review of drugs. Calming agents for certain categories

Menadione sodium bisulfite (menadione)

Composition and release form of the drug

Solution for intramuscular administration colorless or slightly colored, transparent.

Excipients: sodium disulfite, hydrochloric acid 0.1M solution, water for injection.

1 ml - ampoules (5) - contour cell packaging (1) - cardboard packs.
1 ml - ampoules (5) - contour cell packaging (2) - cardboard packs.
2 ml - ampoules (5) - contour cell packaging (1) - cardboard packs.
2 ml - ampoules (5) - contour cell packaging (2) - cardboard packs.

pharmachologic effect

Antihemorrhagic agent. It is a synthetic analogue of K. It is a cofactor for the synthesis of prothrombin and other blood coagulation factors (VII, IX, X) in the liver, and helps normalize the blood coagulation process.

Pharmacokinetics

After oral administration, it is absorbed from the gastrointestinal tract. Protein binding is reversible. Accumulates mainly in the liver, spleen, and myocardium. Converts into vitamin K2 in the body. The conversion process occurs most intensively in the myocardium and skeletal muscles, and somewhat weaker in the kidneys.

Metabolites of vitamin K (monosulfate, phosphate and diglucuronide-2-methyl-1.4-naphthoquinone) are excreted in the urine - up to 70%.

Indications

Hemorrhagic syndrome associated with hypoprothrombinemia; hypovitaminosis K (including with obstructive jaundice, hepatitis, prolonged diarrhea); hemorrhagic disease of newborns; bleeding after wounds, trauma and surgery; in gynecology as part of the complex treatment of dysfunctional uterine bleeding not associated with organic pathology, with menorrhagia. As a specific antagonist for bleeding associated with indirect administration. III trimester of pregnancy (to prevent bleeding in newborns).

Contraindications

Increased blood clotting, thromboembolism, increased sensitivity to menadione.

Dosage

For adults, when taken orally - 15-30 mg/day, intramuscularly - 10-15 mg/day.

Children under 1 year old - 2-5 mg/day, up to 2 years old - 6 mg/day, 3-4 years old - 8 mg/day, 5-9 years old - 10 mg/day, 10-14 years old - 15 mg /day Frequency of administration: 2-3 times/day. The duration of treatment is determined individually.

Maximum doses: for adults, when taken orally, a single dose is 30 mg, a daily dose is 60 mg; with intramuscular administration, a single dose is 15 mg, a daily dose is 30 mg. For newborns - 4 mg/day.

A world filled with opportunities to gain new knowledge gives women the chance to believe that they are fully capable of treating their ailments on their own.

For example, women on their own, without consultation or prescription from a doctor, start taking Vikasol tablets. As a rule, Vikasol is taken during menstruation to change the course of the menstrual cycle.

Let's figure out whether it is worth so selflessly believing in your strength and knowledge, and thus causing irreparable damage to your own health.

Vikasol tablets from a pharmacological point of view

The liquid part of the body - blood, moves through the vessels in the absence of disturbances in the normal rhythm, when there are no problems with blood clotting and there are no blood clots. The most minor deviations from the usual state of aggregation blood lead to disruption of homeostasis. The blood coagulation system is the main component responsible for the absence of bleeding.

Of course, there are some diseases in which blood clotting disorders are at the genetic level, for example, Wergolf's disease, hemophilia. Even hemostatic drugs, for example, Vikasol, are not able to help.

Vikasol is a hemostatic agent or an indirect coagulant, that is, it stimulates the formation of a blood clot that stops bleeding. In fact, Vikasol is an artificial water-soluble analogue of vitamin K (an essential blood clotting factor). The drug has its effect due to menadione sodium bisulfite, and in pharmacies we can find it in the form of tablets or injection solution.

Mechanism of action of Vikasol

The drug, as a synthetic analogue of vitamin K, initiates the synthesis of prothrombin in the liver. This, in turn, triggers a sequential chain of blood clot formation. Based on the mechanism of action, women independently take Vikasol to delay the onset of menstruation and to stop menstrual flow. Thus, the number of discharges and their duration are reduced.

The package insert informs you under what conditions Vikasol is indicated:

vitamin K deficiency in obstructive jaundice;
removal of part of the small intestine;
infectious diseases gastrointestinal tract with hemorrhages, for example, dysentery;
Crohn's disease and ulcerative colitis;
pathology circulatory system eg thrombocytopenic purpura; multiple nasal, dysfunctional uterine, internal bleeding;
diarrhea;
hypothrombinemia;
minute hemorrhages into the layers of the skin;
hemorrhagic disease of newborns;
prolonged massive bleeding after surgery.

The instructions for use do not exclude the item “contraindications”:

increased percentage of blood clotting;
frequent blood clots;
hypercoagulability;
hemolytic disease in newborns.

Particular caution should be exercised with use during pregnancy and lactation, with liver and kidney failure, and glucose-6-phosphate dehydrogenase deficiency.

Vikasol tablets in gynecology

The drug is an official pharmacological drug, which means it can cause side effects. The drug’s help with heavy menstrual bleeding, and even with dysfunctional uterine bleeding, has been known for a long time. Women willingly advise their friends to take it to stop their periods. Women usually find such dubious advice by reading reviews on women's forums. Some reviews help you find answers to your questions, but you should not rely on them, because each body’s reaction is individual to a particular drug. For some reason, women believe that they can take Vikasol whenever necessary, without thinking about the consequences, although the old drug no longer has the best reputation.

Reasons why Vikasol will disappoint a woman:

You will not be able to stop your period immediately with this drug. The active work of Vikasol begins in a day at best, which means by this time you will have already lost a large number of blood (if your periods are excessively heavy or uterine bleeding has begun), and the help of the drug will be late. Vikasol will stop heavy periods only if they are caused by a deficiency of vitamin K;
If Vikasol is taken uncontrollably, serious functional disorders in the body are not far off;
Assessing the reviews of women who once assessed the effectiveness of the medicine on themselves, we can conclude that in every third case side effects appear. That is, it is not possible to stop menstruation on time, and in addition other problems arise, for example, allergic urticaria, tachycardia, increased blood pressure, etc.

How to take the drug to stop menstruation?

As a rule, the package insert is created precisely so that the patient once again reads all the indications, contraindications and risks of taking the medicine, as well as the method of dosing and taking it when different situations.

Quantity side effects, which reviews only partially mention, will be reduced if the medication is prescribed by a gynecologist in accordance with the indications. Taking the drug in tablet form – 0.015 - 0.03 g during the day (2 tablets). Injection form - intramuscularly no more than 0.03 g, that is, 1 injection.

It is prohibited to increase the amount of the substance taken, since excessive intake leads to the rapid development of edema and massive formation of blood clots.

You should not compromise your health, even if the long-awaited vacation comes at the same time as your menstruation. Perhaps taking Vikasol early will reduce the amount of discharge, speed up or even stop menstruation, but soon the body will remind you of such a gross intervention in physiology.

yagotova.ru

Vikasol is a drug that can stop menstruation or make it less intense. But, like any medicine, it must be taken according to certain rules. What do Vikasol instructions for use during menstruation look like?

Vikasol for menstruation

The drug Vikasol is a stimulator of the production of an important protein in the blood, prothrombin, which promotes blood clotting. Essentially, it is a medicine that stops or reduces different types bleeding, including menstrual bleeding. Therefore, it is often prescribed for heavy periods to reduce their intensity.

Participates in the process of synthesizing new elements of biological fluid - stabilizes the general condition of the body, relieves fatigue, and prevents the development of anemia.

Instructions for use during heavy periods

Not all women understand exactly what Vikasol is and what this drug helps with. The medicine can be taken in the form of tablets or intramuscular injections. With the first option, the active substance begins to work after 12 hours, and with the second, almost immediately after administration.

Most often it is prescribed if unusually heavy menstruation has begun. It can be triggered by:

fibroids formed in the ovary;
diseases of the uterine mucosa - endometritis and endometriosis;
hormonal imbalance;
inability of the uterus to contract;
lack of vitamin K;
poor blood clotting.

In these cases, Vikasol is prescribed to stop menstruation, but you need to understand that it does not eliminate the causes of heavy bleeding. The medicine helps to increase the platelet content in the blood, making it clot faster.

Independent use the drug is not the best best idea. It can help some, be useless for others, and even harm others.

The active substance works best if heavy discharge is caused by a deficiency of vitamin K. In many other cases, Vikasol tablets during menstruation can begin to act effectively only after 12-24 hours, and during this time you can lose a lot of blood. This is especially true when we're talking about not about heavy menstruation, but about uterine bleeding.

If you do not consult a gynecologist on how to take Vikasol, you can not only become a victim of side effects, but also lead to serious disorders in the body.

How to take Vikasol during menstruation

Instructions for use of Vikasol during menstruation depend on the form in which the medication was prescribed. The amount of active substance that can be taken per day is 60 mg. These are two tablets or one intramuscular injection. Tablets are usually prescribed before meals, twice a day, 7 days before the expected period, but the doctor can adjust the distribution of the daily dose. You can take the medicine continuously for no longer than 4 days in a row.

It is important to remember that the medicine does not work immediately. Therefore, to stop your period, you should not try to do it by taking a loading dose.

Using the drug in excess of the norm threatens the formation of blood clots, hormonal and menstrual disruption. Blood whose movement has been stopped accumulates in the body and can cause the development of inflammatory process, edema and internal decomposition of blood.

Similar problems are often observed in women who have used a stopping drug to delay the onset of their periods for personal reasons. After such experiments menstrual cycle may take a long time to recover and be accompanied by problems in the reproductive system.

Indications for Vikasol during menstruation

The indications for prescribing Vikasol are usually as follows:

hemorrhagic syndrome due to hypoprothrombinemia;
blood loss after injury, trauma or surgery;
lack of vitamin K.

The latter often occurs if a woman has had jaundice, for a long time suffered from diarrhea, had cirrhosis of the liver or hepatitis.

The use of this medicine has been proven to be highly effective for uterine bleeding and hemorrhagic disease in infants. It is prescribed in case of overdose of drugs that destabilize the amount of vitamin K in the body.

If Vikasol is not used, analogues of this remedy are Dicynon, Etamzilat, Kontriven, Tranexam, Vilate.

They prefer to work with Dicynon and Etamsylate during operations. But analogues also have a number of contraindications. They should not be taken for thrombosis, porphyria and bleeding caused by an overdose of anticoagulants. Also, unlike Vikasol, some analogues cannot be used during pregnancy.

Contraindications

Vikasol during heavy periods should not be taken by those suffering from:

thrombosis;
predisposition or presence of thromboembolism;
high blood clotting rate;
hypercoagulability;
atherosclerosis.

As already mentioned, the excess daily norm can cause the development of many pathologies, so you should not violate the rules of administration. The use of this medicine is considered useless if a woman has von Willebrand disease and Verhof disease or hemophilia.

Side effects

Severe side effects can occur even if the medicine is not abused. This is one of the reasons to carefully consider the need to take it. A third of women who took Vikasol suffer from side effects. It can be:

hives;
severe itching and redness of the skin;
allergic rashes;
lowering blood pressure;
tachycardia;
dizziness;
headache;
destabilization of liver function;
hemolytic anemia;
loss of consciousness;
red spots on the face;
swelling and cramping in asthma sufferers;
change in taste perception.

Due to the risk of side effects and improper absorption of the drug by the body, its use should be monitored by a doctor. During the treatment process, monitoring blood clotting is a necessary aspect.

Vikasol is a drug that is quite effective when it is necessary to reduce menstruation or stop bleeding completely. But its effectiveness does not apply to all cases and the drug does not work immediately after use. Therefore, an independent decision to take this medicine when bleeding is detected may be erroneous. Also, you should not use the medication as a way to delay the onset of your period for several days. Such amateur activities can lead to serious functional disorders reproductive system and the body as a whole.

omesyachnyh.ru

Tablets "Vikasol" to stop menstruation: reviews, features of use and side effects

The drug "Vikasol" is a vitamin preparation of synthetic origin that prevents the development and stopping of bleeding of various etiologies. It has a reversible effect on the blood clotting system and is indicated for people with serious liver diseases and heavy uterine bleeding. It can be taken on later pregnancy.

In this article we will look at how Vikasol is used to stop menstruation. Reviews will also be provided.

Description

The active medicinal substance of the drug "Vikasol" is an analogue of vitamin K, which is responsible for blood clotting in the body. It is a hemostatic and anticoagulant. After absorption into the systemic circulation, it is capable of:

How does the medicine work?

The drug begins to act actively 7–24 hours (depending on the dosage form) after administration. The scheme is as follows:

When released into the blood, it binds to plasma proteins.
Affects the formation of prothrombin and blood coagulation factor IV (production of proconvertin).
Converted to vitamin K.
Excreted through the kidneys in the form of metabolites in the urine.

Many patients use the drug "Vikasol" to stop menstruation. Reviews confirm its effectiveness in in this case.

What dosage forms are there?

The drug can be purchased in pharmacies in the following dosage forms:

In the form of tablets, packaged in packages of 25-50 pieces. Active substance– 0.015 g per tablet.
In the form of ampoules: 1% injection solution with a volume of 1 ml, from 10 to 100 doses per package.

We will tell you below how to take Vikasol to stop menstruation (reviews are also available).

In what cases is it prescribed?

The drug has a pronounced effect in the treatment of diseases that change the composition of the blood and its clotting. We list the main ones:

hypovitaminosis of vitamin K, including hepatitis and jaundice associated with low secretion of bilirubin;
peptic ulcer, colitis, bleeding from the stomach and duodenum;
impaired functioning of the pancreas, small intestine, Crohn's disease;
prolonged nosebleeds, subcutaneous and mucous hemorrhages;
prolonged uterine bleeding (hypermenorrhea);
in order to stop bleeding in the 3rd trimester of pregnancy (prescribed by a doctor).
prevention and treatment of bleeding in newborns;
radiation sickness;

restoration of blood clotting after taking anticoagulants - vitamin K antagonists;
persistent diarrhea, dysentery;
preparation for surgery.

The instructions for the drug do not contain information about the possibility of using Vikasol to stop menstruation. Reviews confirm this.

In veterinary medicine, the drug treats postoperative bleeding and injuries, food poisoning animals.

Contraindications for use

The main contraindications are pregnancy and liver failure. It is not directly prohibited, but it is not recommended to use the drug together with large dose alcohol.

It is also contraindicated to take the medicine if you have the following pathologies:

hypercoagulability syndrome ( increased activity blood coagulation system);
thromboembolism;
jaundice of newborns;
hypersensitivity to the components of the drug.

How to drink Vikasol during menstruation? How to stop bleeding? These are common questions.

Overdose

An overdose of the drug leads to the following symptoms:

itching, urticaria, redness of the skin;
bronchospasms;
dizziness;
drop in blood pressure, tachycardia.

Also, injections can lead to redness of the injection area and the appearance of local allergic reactions. Very rarely, newborns experience convulsions and jaundice. When taken simultaneously with other hemostatic drugs, the risk of adverse reactions increases.

How to use Vikasol Biosynthesis tablets correctly?

Tablets and ampoules for intramuscular injection prescribed in the following dosages:

adults – no more than 30 mg, per day – no more than 60 mg;
the maximum daily dose in pediatrics will be 2 mg (for newborns) and 15 mg (for children and adolescents 10–15 years old);
for elderly people it is recommended to reduce the daily dosage by 2 times;
if there are severe and life-threatening conditions, then it is permissible to increase the dosage of “Vikasol” in the injection solution with the use of additional hemostatic agents with rapid action.

The course lasts on average five days. The regimen for using the drug is prescribed individually. It is influenced by the severity and duration of the disease.

After starting treatment, the prothrombin index of the blood should be monitored.

If simultaneous administration of broad-spectrum antibiotics is required, the effectiveness will decrease, so it is necessary to increase the daily and single dosage.

This is confirmed by the instructions for use for the drug "Vikasol". For heavy periods, only a doctor should prescribe it.

How is the drug used in gynecology?

Women use Vikasol to stop menstruation, as well as when there is heavy menstruation. However, only the attending physician should prescribe the medication, since the use must be justified and safe. The remedy treats:

dysfunctional uterine bleeding based on vitamin K deficiency;
endometritis, endometriosis – prescribed together with other medications;
prolonged bleeding after abortion or in cases of medical termination of pregnancy.

If Vikasol is used uncontrollably during menstruation, it can lead to disturbances in the functioning of the reproductive system, as well as reduce blood clotting, cause allergic reactions, provoke heart rhythm disturbances, a drop or increase in blood pressure.

The permissible dose of the drug should not be exceeded during menstruation (women can do this to reduce the volume and duration of menstruation). This is strictly prohibited, as it is dangerous to life!

If there is an emergency, you can take the drug once to stop your period. This should be done according to the following scheme: 1-2 tablets per day. Do not take the drug for more than 2 days.

We looked at how to use Vikasol to stop menstruation. Reviews confirm the effectiveness of this product.

Reception for pregnant and lactating women

The advisability of using the drug "Vikasol" in pregnant women is decided together with the attending physician. There is no information about the negative effect of the active substance on the fetus.

It is extremely rarely prescribed in the 3rd trimester, when prevention of labor hemorrhages is needed or there is placental abruption. It is taken in combination with vitamin E, injections of “Dicynon”, “No-shpa”. It is not contraindicated during breastfeeding. During pregnancy it is now prescribed extremely rarely.

How is it used for newborns?

If a newborn is diagnosed with a hemorrhagic disease (bleeding of the intestines, stomach and umbilical wound), then he may be prescribed a course consisting of one intramuscular injection, which must be done every three days. In particular difficult cases requires simultaneous blood plasma transfusion.

How to store?

The drug is stored at a temperature no higher than 25 degrees, away from sunlight. To purchase it at a pharmacy, you need a doctor's prescription. Its shelf life is two years.

Compound

1 ml of solution contains the active substance: menadione sodium bisulfite (Vikasol) in terms of menadione sodium bisulfite trihydrate - 10.0 mg.

Pharmacotherapeutic group

Vitamin K analog synthetic

ATX code

pharmachologic effect

A water-soluble analogue of vitamin K (vitamin K3), promotes the synthesis of prothrombin and proconvertin, increases blood clotting by enhancing the synthesis of coagulation factors II, VII, IX, X. It has a hemostatic effect (vitamin K deficiency causes increased bleeding). In the blood, prothrombin (factor II) in the presence of thromboplastin and calcium ions, with the participation of proconvertin (factor VII), factors IX (Christmas factor), X (Stewart-Prower factor) transforms into thrombin, under the influence of which fibrinogen is converted into fibrin, a component the basis of a blood clot (thrombus). Substrate stimulates K-vitamin reductase, which activates vitamin K and ensures its participation in the hepatic synthesis of K-vitamin-dependent plasma hemostasis factors. The onset of the effect is 8-24 hours (after intramuscular injection).

Indications for use

Hemorrhagic syndrome associated with hypoprothrombinemia; hypovitaminosis K (including obstructive jaundice, hepatitis, liver cirrhosis, prolonged diarrhea); bleeding after wounds, trauma and surgery; as part of complex therapy for dysfunctional uterine bleeding, menorrhagia. Treatment and prevention of hemorrhagic disease of newborns. Overdose of vitamin K antagonist drugs (warfarin, phenindione, acenocoumarol).

Contraindications

Hypersensitivity to the components of the drug. Increased blood clotting, thromboembolism. Hemolytic disease of newborns. Pregnancy and lactation period. With caution: glucose-6-phosphate dehydrogenase deficiency, liver failure.

Directions for use and doses

The drug is administered intramuscularly. For adults, a single dose is 10-15 mg, the maximum single dose is 30 mg, the maximum daily dose is 60 mg. In pediatrics: newborns up to 4 mg/day up to 1 year 2-5 mg/day 1-2 years 6 mg/day 3-4 years 8 mg/day 5-9 years 10 mg/day 10-14 years 15 mg/day From the age of 15, the drug is prescribed in the same way as for adult patients. The duration of treatment is 3-4 days, after a four-day break, again for 3-4 days. Daily dose can be divided into 2-3 doses. For surgical interventions with possible severe parenchymal bleeding, it is prescribed for 2-3 days before surgery.

Release form

Solution for intramuscular administration 10 mg/ml. 1 ml or 2 ml in ampoules of colorless neutral glass type I with a colored break ring or with a colored dot and a notch or without a break ring, a colored dot and notch. The ampoules can additionally be coated with one, two or three color rings and/or a two-dimensional barcode, and/or alphanumeric coding, or without additional color rings, a two-dimensional barcode, or alphanumeric coding. 5 ampoules per blister pack made of polyvinyl chloride film and lacquered aluminum foil or polymer film or without foil and without film. Or 5 ampoules are placed in a pre-made form (tray) made of cardboard with cells for laying ampoules. 1 or 2 blister packs or cardboard trays, together with instructions for use and a scarifier or ampoule knife, or without a scarifier and ampoule knife, are placed in a cardboard package (pack).

Instructions

for medical use

medicine

VIKASOL-DARNITSA

Tradename

Vikasol-Darnitsa

International nonproprietary name

Menadione sodium bisulfite

Dosage form

Solution for injection 1% 1 ml

Compound

1 ml of solution contains

active substance - vikasol (menadione sodium bisulfite) 10 mg,

Excipients: sodium metabisulfite (E 223), 0.1 M hydrochloric acid, water for injection.

Description

Transparent colorless or slightly yellowish liquid

Pharmacotherapeutic group

Hemostatics. Vitamin K and other hemostatic agents. Vitamin K. Menadione.

Code ATX В02В А02

Pharmacological properties

Pharmacokinetics

After intramuscular administration, it is easily and quickly absorbed into the systemic circulation. Binding to plasma proteins is reversible. The blood of patients with very low albumin levels binds vitamin K weakly or not at all. Accumulates mainly in the liver, spleen, and myocardium. The most intense metabolic process occurs in the myocardium and skeletal muscles, somewhat weaker in the kidneys. It is excreted by the kidneys and bile almost exclusively in the form of metabolites. Metabolites of vitamin K (monosulfate, phosphate and diglucuronide-2-methyl-1,4-naphthoquinone) are excreted in the urine - up to 70%. High concentrations of vitamin K in feces are due to the fact that it is synthesized by intestinal microflora.

Pharmacodynamics

Vitamin K exists in several forms. The main form of vitamin K is vitamin K 1 (phylloquinone) found in plants, especially green leafy vegetables. Another form of vitamin K is vitamin K 2 (menaquinone), which can be absorbed in limited quantities. It is produced by bacteria in the lower small intestine and large intestine.

Vikasol-Darnitsa is a synthetic analogue of water-soluble vitamin K and is considered as vitamin K 3 (menadione), promotes the synthesis of prothrombin and proconvertin, increases blood clotting by enhancing the synthesis of coagulation factors II, VII, IX, X. It has a hemostatic effect (vitamin K deficiency causes increased bleeding). In the blood, prothrombin (factor II) in the presence of thromboplastin and Ca 2+, with the participation of proconvertin (factor VII), factors IX (Christmas factor, X (Stewart-Prower factor)) transforms into thrombin, under the influence of which fibrinogen is converted into fibrin, which constitutes the basis of a blood clot (thrombus). Vikasol-Darnitsa as a substrate stimulates K-vitamin reductase, which activates vitamin K and ensures its participation in the hepatic synthesis of K-vitamin-dependent plasma hemostasis factors.

The role of vitamin K in humans and animals is not limited to its influence on the biosynthesis of procoagulants. It affects bioenergy and a number of anabolic processes. It is important for the exchange of high-energy compounds and for the formation of ATP. Vitamin K deficiency leads to ATP deficiency and a weakening of the energy supply for the biosynthesis of many compounds. The latter include not only procoagulants, but also other rapidly renewed proteins, including a number of enzymes not directly related to the blood coagulation process. With vitamin K deficiency, the biosynthesis of some biologically active substances non-protein nature: serotonin, histamine, acetylcholine. The onset of the effect is 8-24 hours after intramuscular administration.

Indications for use

Bleeding against the background of hypoprothrombinemia, caused by jaundice, in acute hepatitis, capillary and parenchymal bleeding

After surgery and injuries

Bleeding during peptic ulcer stomach and duodenum

Severe symptoms of acute radiation sickness

Prolonged nosebleeds and hemorrhoids

Hemorrhagic phenomena in premature infants

Uterine premenopausal and juvenile bleeding

Spontaneous bleeding

Preparation for surgery if there is a danger of bleeding in the postoperative period, pulmonary hemorrhages, hemorrhagic phenomena against the background of septic diseases

Bleeding and hypoprothrombinemia caused by an overdose of phenylin, neodicoumarin, and other anticoagulants - vitamin K antagonists

Directions for use and doses

The drug is administered intramuscularly.

For adults single dose - 10 mg, maximum single dose - 15 mg, maximum daily dose - 30 mg.

The duration of treatment is 3-4 days, after a 4-day break the course is repeated if necessary.

For surgical interventions with possible severe parenchymal bleeding, it is prescribed for 2-3 days before surgery.

For children: up to 1 year - 2-5 mg/day, 1-2 years - 6 mg/day, 3-4 years - 8 mg/day, 5-9 years - 10 mg/day, 10-18 years - 15 mg/day days The dose is divided into 2 injections. The duration of treatment is determined by the doctor.

Side effects

Facial hyperemia, skin rash (including erythematous, urticaria), skin itching, bronchospasm
- hemolytic anemia, hemolysis in newborns with congenital deficiency of glucose-6-phosphate dehydrogenase or in patients with vitamin E deficiency, thromboembolism

Transient decrease in blood pressure, tachycardia, weak pulse filling

- reactions at the injection site: pain and swelling at the injection site, discoloration of the skin in the form of spots with repeated injections in the same place. Vikasol can cause local scleroderma
- other: hyperbilirubinemia, jaundice (including kernicterus in infants), dizziness, profuse sweat, change taste sensations, feeling of heat.

Contraindications

Hypersensitivity to the components of the drug

Hypercoagulation, thromboembolism

Hemolytic disease of the newborn

Glucose-6-phosphate dehydrogenase deficiency

Severe liver failure.

Drug interactions

When used simultaneously with oral anticoagulants, the anticoagulant effect may be reduced. Weakens the effect of indirect anticoagulants (including coumarin and indanedione derivatives). Does not affect the anticoagulant activity of heparin. Simultaneous use with broad-spectrum antibiotics, quinidine, quinine, salicylates in high doses, sulfonamides requires an increase in the dose of vitamin K.

When used simultaneously with hemolytic medicines the risk of side effects increases.

When used simultaneously with aggregants and fibrinolysis inhibitors, their hemostatic effect is potentiated.

special instructions

It must be taken into account that when using Vikasol, platelet aggregation may be inhibited. For hemophilia, thrombocytopenic purpura and Werlhof's disease, the drug is not effective.

To prevent hemorrhagic disease of newborns, it is better to use phytomenadione than menadione sodium bisulfite, since it is less likely to cause hyperbilirubinemia and hemolytic anemia in newborns (including premature infants).

Children

The drug is used in pediatric practice.

Pregnancy and lactation

Prescribe with caution during pregnancy.

Vikasol-Darnitsa is a risk drug during pregnancy. The use of the drug in the 2nd and 2nd trimesters is possible according to indications, if the benefit to the mother outweighs the risk to the fetus. Prophylactic administration of vitamin K in the third trimester of pregnancy is ineffective due to its low permeability through the placenta.

If it is necessary to prescribe the drug to women who are breastfeeding, breastfeeding should be stopped for the period of treatment.

Features of the effect of the drug on the ability to drive vehicles and especially dangerous mechanisms

The drug does not affect the reaction rate when driving vehicles or operating other mechanisms. If dizziness is observed during treatment, a decrease in blood pressure should be avoided. vehicle and work with moving mechanisms.

Incompatibility

Vikasol is incompatible with sulfonamide drugs, PAS, salicialates, oxycoumarin. Not compatible in the same syringe with solutions of alkalis and acids. The active ingredient of the drug quickly disintegrates when exposed to direct sunlight.

Overdose

Symptoms: hypervitaminosis K, manifested by hyperprothrombinemia and hyperthrombinemia, hyperbilirubinemia, jaundice, increased activity of liver enzymes; Abdominal pain, constipation or diarrhea, general agitation and agitation, and skin rashes were noted. In isolated cases, children develop toxicosis, manifested by convulsions.

Treatment. The drug is discontinued. Anticoagulants are prescribed under the control of coagulation system parameters. Therapy is symptomatic.

Release form and packaging

1 ml of the drug in glass ampoules.

A label made of paper with a self-adhesive coating is glued onto the ampoule or applied with intaglio printing ink for glass products.

5 ampoules together with a knife for opening the ampoules are placed in a blister pack (cassette).

Two contour blister packs along with instructions for medical use in the state and Russian languages are placed in a pack.

10 ampoules, along with instructions for medical use in the state and Russian languages and a knife for opening ampoules, are placed in a box with a corrugated liner.

When packaging ampoules with a colored break ring, or a colored break point, the placement of knives for opening the ampoules is excluded.

Storage conditions

Store in original packaging at temperatures from 2°C to 8°C.

Keep out of the reach of children!

Shelf life

Do not use after expiration date

Conditions for dispensing from pharmacies

On prescription

Manufacturer/packer

PJSC "Pharmaceutical Firm "Darnitsa"

Ukraine, 02093, Kyiv, st. Boryspilskaya, 13.

Registration Certificate Holder

PJSC "Pharmaceutical Firm "Darnitsa", Ukraine

The address of the organization that receives claims from consumers regarding product quality on the territory of the Republic of Kazakhstan is

phone/fax: (+ 380 44) 207 73 27

Have you completed sick leave due to back pain?

How often do you face the problem of back pain?

Can you tolerate pain without taking painkillers?

Find out more how to deal with back pain as quickly as possible

Trade name:

Vikasol

International nonproprietary name:

menadione sodium bisulfite

Dosage form:

solution for intramuscular administration

Composition per 1 ml:

Activesubstance: menadione sodium bisulfite (Vikasol) in terms of menadione sodium bisulfite trihydrate - 10.0 mg;

Auxiliarysubstances: sodium disulfite – 1.0 mg, 0.1 M hydrochloric acid solution – up to pH 2.2-3.5, water for injection – up to 1.0 ml.

Description:

clear, colorless or slightly colored yellow or green-yellow liquid.

Pharmacotherapeutic group:

vitamin K analog synthetic

CodeATX: B02BA02

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

In the blood, prothrombin (factor II) in the presence of thromboplastin and calcium ions, with the participation of proconvertin (factor VII), factors IX (Christmas factor), X (Stewart-Prower factor) transforms into thrombin, under the influence of which fibrinogen is converted into fibrin, a component the basis of a blood clot (thrombus).

Substrate stimulates K-vitamin reductase, which activates vitamin K and ensures its participation in the hepatic synthesis of K-vitamin-dependent plasma hemostasis factors. The onset of the effect is 8-24 hours (after intramuscular injection).

Pharmacokinetics

After intramuscular administration, it is easily and quickly absorbed. Accumulates in tissues in small quantities. After going through a cycle of metabolic activation, it is oxidized in the liver to the diol form. It is excreted by the kidneys and bile mainly in the form of metabolites. High concentrations of vitamin K in feces are due to its synthesis by intestinal microflora.

INDICATIONS FOR USE

CONTRAINDICATIONS

Hypersensitivity to the components of the drug. Increased blood clotting, thromboembolism. Hemolytic disease of newborns. Pregnancy and lactation period.

WITHcaution: deficiency of glucose-6-phosphate dehydrogenase, liver failure.

USE IN PREGNANCY AND BREASTFEEDING

Experimental studies in animals have revealed adverse effects on the fetus. Controlled studies of the use of Vikasol in pregnant women have not been conducted. Use during pregnancy and childbirth is contraindicated (risk of developing hemolytic anemia, hyperbilirubinemia and kernicterus in the fetus and newborn). Breastfeeding should be stopped while using the drug.

METHOD OF APPLICATION AND DOSES

The drug is administered intramuscularly. For adults, a single dose is 10-15 mg, the maximum single dose is 30 mg, the maximum daily dose is 60 mg. In pediatrics:

From the age of 15, the drug is prescribed in the same way as for adult patients.

The duration of treatment is 3-4 days, after a four-day break, again for 3-4 days. The daily dose can be divided into 2-3 doses. For surgical interventions with possible severe parenchymal bleeding, it is prescribed for 2-3 days before surgery.

SIDE EFFECT

Allergic reactions: hives

Blood disorders: hemolytic anemia, hemolysis in newborns with congenital deficiency of glucose-6-phosphate dehydrogenase.

Nervous system disorders: dizziness; change in taste sensations.

Violations by respiratory system, organs chest and mediastinum: bronchospasm.

Cardiovascular system disorders: transient decrease in blood pressure, tachycardia, “weak” pulse filling.

Disorders of the liver and biliary tract: jaundice (including kernicterus in newborns).

Disorders of the skin and subcutaneous tissues: facial hyperemia, skin rash (including erythematous), skin itching.

General disorders and disorders at the injection site: pain and swelling at the injection site, skin lesions in the form of spots with repeated injections into the same place; "profuse" sweat.

Laboratory and instrumental data: hyperbilirubinemia.

The disulfite contained in the drug can, in rare cases, cause severe hypersensitivity reactions and bronchospasm.

OVERDOSE

Symptoms: hypervitaminosis K, manifested by hyperprothrombinemia (which may be accompanied by thrombosis), hemolytic anemia, hyperbilirubinemia. In isolated cases, especially in children, seizures develop.

Treatment: drug withdrawal, symptomatic therapy. In some cases, it is possible to prescribe direct anticoagulants (unfractionated heparin) under the control of blood coagulation parameters.

INTERACTION WITH OTHER MEDICINES

Weakens the effect of indirect anticoagulants (including coumarin and indanedione derivatives).

Does not affect the anticoagulant activity of direct anticoagulants (including heparin).

Simultaneous administration with broad-spectrum antibiotics, quinidine, quinine, salicylates in high doses, sulfonamide drugs requires an increase in the dose of vitamin K.

The simultaneous administration of Vikasol with drugs that can cause hemolysis increases the risk of side effects.

SPECIAL INSTRUCTIONS

For hemophilia, von Willebrand's disease and Werlhof's disease, the drug is ineffective.

In patients with glucose-6-phosphate dehydrogenase deficiency, Vikasol can cause hemolysis.

Parenteral administration of the drug Vikasol is indicated in cases where it is impossible to take vitamin K preparations orally, as well as in diseases that lead to disruption of the outflow of bile.

InfluenceonabilityToleadernuyumotor transportAndmanagementmechanisms

RELEASE FORM

Solution for intramuscular administration 10 mg/ml.

1 ml or 2 ml in ampoules of colorless neutral glass type I with a colored break ring or with a colored dot and a notch or without a break ring, a colored dot and notch. The ampoules may additionally be coated with one, two or three color rings and/or a two-dimensional barcode, and/or alphanumeric coding, or without additional color rings, a two-dimensional barcode, or alphanumeric coding.

5 ampoules per blister pack made of polyvinyl chloride film and lacquered aluminum foil or polymer film or without foil and without film. Or 5 ampoules are placed in a pre-made form (tray) made of cardboard with cells for laying ampoules. 1 or 2 blister packs or cardboard trays, together with instructions for use and a scarifier or ampoule knife, or without a scarifier and ampoule knife, are placed in a cardboard package (pack).

Storage conditions

In a place protected from light at a temperature not exceeding 25 ° C.

Do not freeze.

Keep out of the reach of children.

Best before date

3 years. Do not use after expiration date.

Vacation conditions

Legal address:

445351, Russia, Samara region, Zhigulevsk, st. Pesochnaya, 11

Address of place of production (address for correspondence, including for receiving claims):

445351, Russia, Samara region, Zhigulevsk, st. Gidrostroiteley, 6-A